Glutamine and Cancer: What do we know?

Reviewer: Paul Anderson, ND

Reference: Michalak KP, et.al. Key Roles of Glutamine Pathways in Reprogramming the Cancer Metabolism. Oxidative Medicine and Cellular Longevity. Volume 2015, Article ID 964321, 14 pages. http://dx.doi.org/10.1155/2015/964321

Design: Literature review

Practice Implications:

l-Glutamine the amino acid is one of the most widely used therapeutic substances in natural and integrative clinics as well as some allopathic practices.  It has benefit in gastrointestinal illnesses and repair, post-surgical care, renal support, muscle mass maintenance, cachexia and a number of other conditions.  Given its wide use in the integrative medical community the concern regarding potential for any adverse or untoward event associated with its use is significant.  The primary potential issue is the “feeding” of cancer cells and another related issue is increasing glutathione stores and thereby inactivating standard therapies.

Likely the most concerning of all potential adverse events is potentiation of cancer in a person using therapeutic l-Glutamine (GLN).  As with many considerations in medicine it is not a simple answer.  The authors state “In analyzing GLN intake as a possible positive or negative factor supporting the cancer growth and/or cancer treatment, one must take into consideration the differences between the metabolism of healthy and cancer cells. The main problem of this analysis is the variety of metabolic changes characterizing different cancer types. Individual types of cancer metabolism should be analyzed with regard to the possible positive or negative effect of glutamine supplementation. Some methods of metabolic analysis of cancer cells are available.”  They then proceed to elaborate on many of the variations in cancer cells that may cause a difference in metabolism in the presence of GLN.

The authors take an exhaustive look at GLN metabolism in normal and cancerous cells, outlining and elucidating differences in GLN metabolism.  What they clearly show is that a simplistic view of the role of GLN in oncology just cannot do justice to the topic.  Factors which may alter considerations in the patient with cancer include dose, timing, tumor type and patient depletion.

Potential GLN benefits include but are not limited to:

  • Post-surgical healing
  • GI repair and maintenance
  • Immune system recovery and maintenance
  • Muscle cell maintenance and recovery
  • Glutathione pool restoration
  • HIF-1 alpha inhibition
  • And others

In cancer metabolism there is a deterioration of Pyruvate dehydrogenase complex (PDHC) and oxidative phosphorylation (OXPHOS) leading to safety when GLN is in the system.  Broadly speaking there are few tumor types that oppose this metabolic change.  The availability of GLN even in a supplemented person is often too low to do much more than feed the deficient GI cells, so peripheral use is limited with oral doses.  The one common exception is glioblastoma multiforme (GM).  In the case of GM, it is theoretically possible that amounts of GLN that were able to cross the GI barrier could be metabolized in a manner promoting of GM energy and health.  In the case of GM the authors point out that restricting carbohydrates would likely make the GLN effective in an anti-GM biology.  They state: “Thus, the supplementation of GLN as the source of NADH2/FADH2 for the impaired OXPH chain producing many ROS can be potentially beneficial in this case. It should be, however, accompanied with the strong carbohydrate reduction in the diet and/or with the glycolysis inhibition therapy and/or with the increase in amino- and fatty acids in the diet that supports TCA cycle and in this way the oxidative stress in the cell.”

Take home points for practice:

  1. GLN oral supplementation is likely safe across most tumor types in patients with cancer.
  2. In cases of GI damage (during or after chemotherapy and radiation) GLN is indicated.
  3. In patients with post oncology therapy depletion or cachexia restoration of the GLN pool is critical to survival.
  4. In active cancers, especially those with active PDHC and OXPHOS, carbohydrate restriction improves the safety of GLN supplementation.
  5. In our clinics the standard uses of GLN in the oncology patient are as follows:

a. During and after chemotherapy and radiation GLN powder in liquid or a soft food 1-3 grams BID-TID and HS
b. In cases of post GI surgery recovery 4-6 grams PO TID
c. In active cancer therapy where GLN supplementation is indicated:
i. Dietary carbohydrate restriction
ii. Other metabolic therapies (DCA, LAMC etc.)
d. In cachexia we will replete the patient using oral and IV protocols.

The authors quote “Based on the analysis of GLN metabolism, it can be concluded that if the OXPH chain is deteriorated, GLN cannot be an effective source of ATP for the cancer cell regardless of the metabolic pathway.” As well as my clinical experience indicates that l-Glutamine used appropriately is an excellent adjunctive therapy in the oncology setting.

About the Clinical Research Update

Keeping up with the latest published clinical research - for healthcare professionals only.

Dr. Paul S. Anderson is medical director of Anderson Medical Specialty Associates, a clinic focusing on the care of patients with cancer and chronic diseases. Former positions include professor of Pharmacology and Clinical Medicine at Bastyr University and Chief of IV Services for Bastyr Oncology Research Center. He is a graduate of National College of Natural Medicine and began instructing classes at naturopathic medical schools in the early 1990’s. He continues to hold board review classes and CME courses for most of the US and Canadian ND programs. He also is a founding board member of the Academy of Parenteral Therapies specialty group and an instructor and author for the International IV Nutritional Therapy training group

Along with research abstracts, news stories, patient handouts and other practice resources, Commentaries are posted in the Practice Resource Center of our website under Emerson Authors:**

**Please remember to login to to view this section.

For questions or comments please
contact Customer Support at:
Email: cs@emersonecologics.com or call 800.654.4432